F. Eskens

440 total citations
20 papers, 366 citations indexed

About

F. Eskens is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, F. Eskens has authored 20 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Molecular Biology and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in F. Eskens's work include Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Angiogenesis and VEGF in Cancer (4 papers). F. Eskens is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Colorectal Cancer Treatments and Studies (4 papers) and Angiogenesis and VEGF in Cancer (4 papers). F. Eskens collaborates with scholars based in Netherlands, United States and Japan. F. Eskens's co-authors include Leni van Doorn, Jaap Verweij, André Planting, Elisabeth G.E. de Vries, Peter Stopfer, A. Amelsberg, Holger Huisman, Jourik A. Gietema, Constantijne H. Mom and Henry Burger and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

F. Eskens

19 papers receiving 357 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. Eskens Netherlands 10 244 189 153 40 29 20 366
Hiroto Kishi Japan 10 245 1.0× 145 0.8× 208 1.4× 27 0.7× 34 1.2× 21 435
Susan E. Jorge Brazil 7 137 0.6× 200 1.1× 112 0.7× 41 1.0× 15 0.5× 22 303
L. Hart United States 11 254 1.0× 183 1.0× 220 1.4× 43 1.1× 7 0.2× 25 518
Amandine Quivy France 6 214 0.9× 121 0.6× 83 0.5× 23 0.6× 19 0.7× 9 351
Luke Walker United States 10 272 1.1× 255 1.3× 253 1.7× 90 2.3× 17 0.6× 39 489
Amy Barone United States 9 217 0.9× 87 0.5× 102 0.7× 43 1.1× 18 0.6× 14 396
Andrew Thomason United Kingdom 4 152 0.6× 151 0.8× 128 0.8× 15 0.4× 18 0.6× 7 369
Guilherme Harada Brazil 11 155 0.6× 161 0.9× 90 0.6× 14 0.3× 15 0.5× 40 317
Sumiko Okubo Japan 10 165 0.7× 68 0.4× 116 0.8× 17 0.4× 11 0.4× 25 296
Wee-Lee Yeo Singapore 7 494 2.0× 507 2.7× 223 1.5× 41 1.0× 15 0.5× 11 657

Countries citing papers authored by F. Eskens

Since Specialization
Citations

This map shows the geographic impact of F. Eskens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Eskens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Eskens more than expected).

Fields of papers citing papers by F. Eskens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Eskens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Eskens. The network helps show where F. Eskens may publish in the future.

Co-authorship network of co-authors of F. Eskens

This figure shows the co-authorship network connecting the top 25 collaborators of F. Eskens. A scholar is included among the top collaborators of F. Eskens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Eskens. F. Eskens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bins, Sander, Leni van Doorn, Mitch A. Phelps, et al.. (2017). Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide. Clinical and Translational Science. 10(4). 271–279. 23 indexed citations
3.
Langenberg, Marlies H.G., Vincent A. de Weger, Robert Frank, et al.. (2016). A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma. European Journal of Cancer. 69. S34–S34. 3 indexed citations
4.
5.
Puglisi, M., Leni van Doorn, Montserrat Blanco-Codesido, et al.. (2011). A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 2518–2518. 17 indexed citations
6.
Herpen, C. van, F. Eskens, Ingrid M.E. Desar, et al.. (2008). 344 POSTER A phase Ib dose escalation study to evaluate safety and tolerability of the combination of the aminopeptidase inhibitor CHR-2797 and paclitaxel in patients with advanced or treatment refractory tumors. European Journal of Cancer Supplements. 6(12). 109–109. 1 indexed citations
7.
Jonge, Maja J.A. de, Neeltje Steeghs, Jaco J. Verweij, et al.. (2008). Phase I study of the aurora kinases (AKs) inhibitor PHA-739358 administered as a 6 and 3-h IV infusion on Days 1, 8, 15 every 4 wks in patients with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 3507–3507. 6 indexed citations
8.
9.
Gelderblom, Hans, Jaco J. Verweij, Neeltje Steeghs, et al.. (2006). 72 POSTER Phase I, safety, pharmacokinetic and biomarker study of telatinib (BAY 57-9352), an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors. European Journal of Cancer Supplements. 4(12). 26–26. 3 indexed citations
10.
Zuehlsdorf, Michael, O. Christensen, Dirk Strumberg, et al.. (2006). VEGF, sVEGFR-2, bFGF, and IL-8 as biomarkers of the pharmacological activity of BAY 57–9352, an oral VEGFR-2 receptor tyrosine kinase inhibitor, in patients with solid tumors. Journal of Clinical Oncology. 24(18_suppl). 3035–3035.
11.
Jonge, Maja J.A. de, Neeltje Steeghs, Jaco J. Verweij, et al.. (2006). 27 ORAL Phase I dose escalation study of the aurora kinase inhibitor PHA-739358 administered as a 6-hour infusion on days 1, 8 and 15 every 4 weeks in patients with advanced/metastatic solid tumors. European Journal of Cancer Supplements. 4(12). 12–12. 7 indexed citations
12.
Savage, S., Jaap Verweij, F. Eskens, et al.. (2006). A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. Journal of Clinical Oncology. 24(18_suppl). 3088–3088. 21 indexed citations
13.
14.
Gelderblom, Hans, Jaco J. Verweij, Neeltje Steeghs, et al.. (2006). Phase I, safety, pharmacokinetic and biomarker study of BAY 57–9352, an oral VEGFR-2 inhibitor, in a continuous schedule in patients with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 3040–3040. 3 indexed citations
15.
Stopfer, Peter, A. Amelsberg, Holger Huisman, et al.. (2005). Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.. Data Archiving and Networked Services (DANS). 6 indexed citations
16.
Vos, Filip De, Ronald Hoekstra, F. Eskens, et al.. (2004). Dose-finding and pharmacokinetic study of ABT-510 with gemcitabine and cisplatin in patients with advanced cancer. Journal of Clinical Oncology. 22(14_suppl). 3077–3077. 4 indexed citations
17.
Polée, M., H.W. Tilanus, F. Eskens, et al.. (2003). Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus. Annals of Oncology. 14(8). 1253–1257. 14 indexed citations
18.
Bent, Martin J. van den, et al.. (1999). Phase II Study of Weekly Dose-intensified Cisplatin Chemotherapy with Oral Etoposide in Recurrent Glioma. Journal of Neuro-Oncology. 44(1). 59–64. 9 indexed citations
19.
Eskens, F., et al.. (1998). Pancreatic islet cell tumor producing vasoactive intestinal polypeptide and calcitonin.. PubMed. 17(6D). 4667–70. 9 indexed citations
20.
Eskens, F.. (1995). Septic shock caused by group G β-haemolytic streptococci as presenting symptom of acute myeloid leukaemia. The Netherlands Journal of Medicine. 46(3). 153–155. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroto Kishi Breakdown of academic impact, for papers by Susan E. Jorge Breakdown of academic impact, for papers by L. Hart Breakdown of academic impact, for papers by Amandine Quivy Breakdown of academic impact, for papers by Luke Walker Breakdown of academic impact, for papers by Amy Barone Breakdown of academic impact, for papers by Andrew Thomason Breakdown of academic impact, for papers by Guilherme Harada Breakdown of academic impact, for papers by Sumiko Okubo Breakdown of academic impact, for papers by Wee-Lee Yeo
Rankless by CCL
2026